View Older Stories View More Recent Stories

Nov 21, 2018 02:15PM AbbVie (ABBV) Receives US FDA Accelerated Approval for VENCLEXTA to Treat AML
Nov 21, 2018 02:14PM AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Nov 20, 2018 08:37AM AbbVie (ABBV) to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at ASH
Nov 20, 2018 08:32AM AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual M
Nov 15, 2018 03:00AM Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
Nov 14, 2018 05:40PM AbbVie (ABBV) Presents Positive Phase 3 Data Showing Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at AAGL
Nov 14, 2018 05:35PM AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
Nov 13, 2018 11:31AM AbbVie (ABBV) Says MAVYRET Shows High Virologic Cure Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Nov 13, 2018 11:30AM AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Nov 13, 2018 08:00AM AbbVie to Present at the Evercore ISI Conference
Nov 9, 2018 08:00AM AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset
Nov 6, 2018 05:05PM AbbVie (ABBV) Announces HUMIRA Global Patent License with Momenta (MNTA)
Nov 6, 2018 04:45PM AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta
Nov 2, 2018 07:47AM AbbVie Reports Third-Quarter 2018 Financial Results
Nov 1, 2018 07:11AM From pharma to prisons, election-sensitive stocks that could swing
Nov 1, 2018 05:59AM AbbVie (ABBV) Granted European Commission Approval of VENCLYXTO (venetoclax) Plus Rituximab
Nov 1, 2018 12:02AM AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Oct 31, 2018 04:54PM AbbVie (ABBV) Phase 3 Trial Evaluating Venetoclax Combination as First-Line Therapy in CLL Met its Primary Endpoint
Oct 31, 2018 04:14PM AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia
Oct 24, 2018 04:09PM AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Oct 23, 2018 09:00AM AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
Oct 22, 2018 06:01PM Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis
Oct 18, 2018 08:51AM AbbVie (ABBV) Announces Global Resolution of HUMIRA Patent Disputes with Fresenius
Oct 18, 2018 08:50AM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi
Oct 18, 2018 08:03AM AbbVie (ABBV), Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Oct 18, 2018 08:00AM AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Oct 17, 2018 08:04AM AbbVie (ABBV) Announces sNDA Accepted for Priority Review by FDA for IMBRUVICA in Combination with Obinutuzumab for Previously Untreated CLL
Oct 17, 2018 08:00AM AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lym
Oct 16, 2018 12:42PM AbbVie (ABBV) Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at UEG
Oct 16, 2018 12:38PM AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
Oct 11, 2018 04:33PM AbbVie (ABBV) Announces Resolution of HUMIRA Patent Disputes with Sandoz
Oct 11, 2018 04:32PM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz
Oct 8, 2018 08:41AM AbbVie (ABBV) to Present New Data for Upadacitinib and HUMIRA at ACR/ARHP Meeting
Oct 8, 2018 08:33AM AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
Sep 21, 2018 07:30AM AbbVie (ABBV) Announces Positive CHMP Opinion for Combination of VENCLYXTO with Rituximab
Sep 21, 2018 07:27AM AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymph
Sep 17, 2018 08:00AM AbbVie to Host Third-Quarter 2018 Earnings Conference Call
Sep 13, 2018 09:20AM AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Sep 13, 2018 06:24AM AbbVie (ABBV) Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing 'Significant Improvements' in Health-Related Quality of Life
Sep 13, 2018 06:20AM AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Sep 11, 2018 08:21AM AbbVie (ABBV) Says Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA Label
Sep 11, 2018 08:17AM Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
Sep 7, 2018 11:23AM AbbVie Declares Quarterly Dividend
Sep 4, 2018 09:00AM AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Aug 28, 2018 08:00AM AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
Aug 22, 2018 08:33AM AbbVie (ABBV), Neurocrine (NBIX) Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 22, 2018 08:30AM AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 22, 2018 06:01AM argenx (ARGX) Reports Exclusive Option Exercise by AbbVie (ABBV) to Develop and License ARGX-115
Aug 17, 2018 08:06AM AbbVie (ABBV) Enters Clinical Research Collaboration with Tolero Pharmaceuticals, Inc. for Acute Myeloid Leukemia Trial
Aug 7, 2018 08:16AM Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
View More Recent Stories View Older Stories